Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Jaap Verweij et al.|The Lancet Oncology|2014Cited by 1.2k
The Clinical Approach Towards ChondrosarcomaHans Gelderblom, Judith V.M.G. Bovée, Pancras C.W. Hogendoorn et al.|The Oncologist|2008Cited by 738
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Beate Timmermann, Ken Brown et al.|European Journal of Cancer|2019Cited by 724
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upPancras C.W. Hogendoorn, D. Vanel, Nick Athanasou et al.|Annals of Oncology|2010Cited by 718
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa Marina, Lisa A. Teot, Sigbjørn Smeland et al.|The Lancet Oncology|2016Cited by 537